A national multicentre study on severe paediatric recurrent idiopathic pericarditis treated with IL-1 blockers: appropriateness of the standard of care and pros and cons of anti-IL-1 treatments

Authors :: R. Caorsi
A. Insalaco
F. Bovis
G. Martini
M. Cattalini
M. Chinali
A. Rimini
C. Longo
S. Federici
C. Celani
G. Filocamo
R. Consolini
M. C. Maggio
G. Fadanelli
F. Licciardi
M. Romano
B. Teruzzi
A. Taddio
A. Miniaci
F. La Torre
A. De Fanti
G. Cavalli
B. Bigucci
R. Gallizzi
M. Chinello
A. Brucato
M. Imazio
R. Cimaz
F. De Benedetti
M. Gattorno
R. Caorsi, A. Insalaco, F. Bovis, G. Martini, M. Cattalini, M. Chinali, A. Rimini, C. Longo, S. Federici, C. Celani, G. Filocamo, R. Consolini, M.C. Maggio, G. Fadanelli, F. Licciardi, M. Romano, B. Teruzzi, A. Taddio, A. Miniaci, F. La Torre, A. De Fanti, G. Cavalli, B. Bigucci, R. Gallizzi, M. Chinello, A. Brucato, M. Imazio, R. Cimaz, F. De Benedetti, M. Gattorno
Publication Year :: 2020
Abstract: Recurrent pericarditis (RP) is a rare cause of morbidity in children. Non-steroidal anti-inflammatory drugs (NSAIDs), glucocorticoids and colchicine are the standard of care in adults. Recently, anakinra has been proven to be effective in patients with steroid-dependence and colchicine resistance.

Subjects :: Settore MED/38 - Pediatria Generale E Specialistica
Recurrent pericarditis, Non-steroidal anti-inflammatory drugs,colchicine resistance

Tools